Multidisciplinary Content Validation of the GiriMok Point-of-Care Protocol for Neonatal Cyanotic Congenital Heart Disease.

Authors

Girish Gupta, Syed Moiz Ahmed, Richa Joshi, Shantanu Shubham

Published in

Cureus. Volume 18. Issue 5. Pages e109877. Epub May 29, 2026.

Abstract

Background Neonatal cyanotic congenital heart disease is a time-critical emergency requiring immediate bedside decision-making. Current guidelines lack a validated, comprehensive point-of-care (POC) protocol suitable for frontline clinicians in diverse settings. The GiriMok Protocol was developed to bridge this gap. This study aimed to develop and establish the content validity of the GiriMok POC Protocol through a rigorous four-phase iterative multidisciplinary expert validation process. Methodology This four-phase study comprised two external validation phases and two author-led refinement phases. Phase 1 involved 18 multidisciplinary experts using a 33-parameter mixed-methods instrument. Phase 2 consisted of focused revalidation by five specialists (neonatologists and a pediatric cardiologist) using a 16-item instrument with modified kappa (k*) computation. Phases 3 and 4 involved evidence-referenced enhancements against 2023-2025 guidelines and final quality assurance. Content Validity Index (CVI) was calculated at item (I-CVI) and scale (S-CVI/Ave) levels. Results In total, 18 unique validators participated across 24 episodes. Phase 1 yielded an S-CVI/Ave of 0.927, with all items meeting the I-CVI ≥0.78 threshold and zero safety concerns. Phase 2 achieved perfect scores (S-CVI/Ave = k* = 1.000) following the integration of a 22-item revision agenda. In total, 35 expert-informed corrections resulted in the final publication-ready GiriMok V4.0. Conclusions The GiriMok POC Protocol achieved unanimous multidisciplinary validation. The perfect Phase 2 CVI demonstrates methodological rigor and responsiveness to expert feedback. The protocol is now positioned for prospective clinical evaluation and national dissemination as a neonatal emergency decision-support tool.

PMID:
42371433
Bibliographic data and abstract were imported from PubMed on 29 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.